Associations of lipoprotein(a) concentrations with cardiovascular disease in men and women with primary hypercholesterolemia Authors: Jakub Kurdziel, Andrzej Fedak, Agnieszka Micek, Przemysław Miarka, Maciej T. Małecki, Małgorzata Waluś-Miarka Published: 2026 ABSTRACT Lipoprotein(a) [Lp(a)] is a useful marker for cardiovascular risk stratification. Previous studies have shown higher Lp(a) levels in women than in men and sex differences in its association with atherosclerosis. The aim of this study was to assess associations between Lp(a) levels and cardiovascular disease (CVD) in men and women with suspected familial hypercholesterolemia (FH).The study included 220 hypercholesterolemic patients (110 men) treated at an outpatient lipid clinic. Clinical data, anthropometric measurements, and laboratory tests were collected. Lipid concentrations were measured enzymatically and Lp(a) by latex-enhanced immunonephelometry. Coronary artery disease (CAD) was present in 27.3% of men and 14.5% of women; 30.9% were current smokers and 84.5% received statin therapy. Median Lp(a) levels were significantly higher in women with CAD than without CAD, whereas no significant difference was observed in men. After age standardization, mean Lp(a) levels did not differ by CAD status in either sex. In age-adjusted logistic regression, CAD in men was associated with smoking and hypertension, while in women it was associated with LDL-C, Lp(a), and smoking.These findings support sex-specific differences in the role of Lp(a) in CAD development and identify Lp(a) as a CVD risk factor in hypercholesterolemic women. Background Lipoprotein(a) [Lp(a)] is a useful marker for cardiovascular risk stratification [[1], [2], [3]]. Recently published systematic meta-analysis provided further evidence that higher Lp(a) levels are associated not only with CVD-death in the general population and in patients with CVD, but also with higher risk of all-cause mortality [2]. Moreover, Lp(a) concentration was associated not only with first, but also with future cardiovascular disease and CAD events [4]. Some previous studies showed that serum Lp(a) levels were higher in females [5] than in males and revealed sex differences in the association between Lp (a) and coronary artery disease and carotid atherosclerosis [6,7]. Lp(a) levels are determined genetically, although, current evidence supports also a role for diet, hormones and related conditions, and liver and kidney diseases in modifying Lp(a) levels [8,9]. Familial hypercholesterolemia (FH) is a genetic disorder of lipid metabolism, characterized by markedly increased LDL-cholesterol and high risk of atherosclerosis and coronary artery disease [10]. Patients with FH had a nearly 2-fold higher prevalence of elevated Lp(a) compared with patients with non-FH primary hyperlipidemia or persons in the general population [[11], [12], [13]]. Elevations in Lp(a) frequently accompany the high levels of LDL in patients with FH and independently correlate with premature-onset CAD [13]. The sex differences in Lp (a) atherogenicity in FH men and women is an aspect often neglected in research studies and clinical practice. Further studies are required to evaluate sex differences in the role of Lp(a) as coronary risk factor between FH men and women, and what patients groups may benefit from Lp(a) screening. The aim of the present study was to assess the associations of Lp (a) levels and cardiovascular diseases in men and women with familial hypercholesterolemia. Methods: This study included 220 patients with suspected familial hypercholesterolemia, treated at an outpatient lipid center. All participants were of Caucasian ethnicity (Polish population). Patients were referred to the center due to suspicion of familial hypercholesterolemia or resistance to ongoing lipid-lowering therapy. Diagnosis of familial hypercholesterolemia was based on Simon Broome criteria [14]. Genetic testing was completed in 116 patients, as the waiting time for genetic testing results is approximately 6–12 months, with 65 patients having genetically confirmed familial hypercholesterolemia. In the remaining patients, the diagnosis was based on clinical criteria according to the Simon Broome criteria, with 6 patients classified as definite FH and 149 as possible FH. Genetic analysis was performed using NGS and MLPA [15,16]. In each patient standardized questionnaire, including past history, family history, smoking habits and drug use was collected. In all patients lipid profile, Lp(a), liver enzymes, urine analysis, TSH, glucose and creatinine was performed. Secondary causes of hyperlipidemia including hypothyroidism, liver disease, and renal disease, were excluded. Anthropometric measurements of weight, height, waist and hip circumference as well as blood pressure measurements were performed. Serum lipid concentrations were determined by enzymatic methods, lipoprotein Lp(a) by latex-enhanced immunonephelometry. Elevated Lp(a) was defined as ≥0.3 g/L (30 mg/dL), representing the lower threshold for increased cardiovascular risk. Cardiovascular disease was diagnosed as past history of myocardial infarction, stents, CABG, or obstruction of coronary arterial vessel above 50%, stroke or transient ischemic attack. Coronary artery disease (CAD) was defined based on medical history as previous myocardial infarction, prior coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting), or the presence of ≥50% stenosis in coronary arteries on computed tomography. CAD reflected established, chronic disease rather than acute events. Arterial hypertension was defined as arterial pressure above 130/80 mmHg or treated hypertension. Statistical analysis included calculations of means (x) and standard deviations (sd) for continuous, normally distributed variables or medians (Me) and interquartile ranges (IR), when variable was not normally distributed. Student's t-test or Mann-Whitney U test (as appropriate) were used to determine the differences between means (distributions) of studied variables between men and women. Multivariable stepwise backward logistic regression analyses including Lp(a), BMI, LDL-C, smoking status, diabetes, arterial hypertension after adjustment for age were performed to assess which factors are associated with the occurrence of CAD in men and in women. Values of p < 0.05 were considered as statistically significant. The study was performed in accordance with the principles of the Declaration of Helsinki and all patients gave written informed consent before inclusion. Institutional review board approval was obtained in Jagiellonian University (1072.6120.133.2022). Results We examined 220 hyperlipidemic persons (110 men) with mean (x±SD) age in men 47.7 ± 14.2, in women 50.5 ± 15.7 yrs (p = 0.1739). The mean levels of LDL-C (x, SD) were significantly lower in men than in women: 3.1 ± 1.7 and 3.8 ± 1.7 mmol/l (p = 0.0017). Also total cholesterol and HDL-C were significantly lower in men than in women while triglyceride levels were lower in women than in men. The median (interquartile range IR) of serum Lp(a) concentration did not differ between men and women: 0.11 (0.57) and 0.20 (0.50) g/L respectively (p = 0.0558). The mean values of BMI, blood pressure, ALT, glucose and creatinine were significantly higher in men than in women (Table 1).Table 1Characteristic of studied variables in men and women.Table 1ParametersMenWomenpNx/Mesd/IRNx/Mesd/IRAge [yrs]11047.714.2311050.515.710.1729TC [mmol/l]1105.121.8791096.111.8420.0001HDL-C [mmol/l]1101.270.4111091.640.471<0.001LDL-C [mmol/l]1103.131.7311103.861.7000.0017TSH []a871.701.06991.511.070.2019TG [mmol/l]a1101.702.061101.190.870.0004Lp(a) [g/l]a1100.110.571100.200.500.0558Glucose [mmol/l]a835.390.86945.160.730.0003Creatinine [mg/l]a10580.617.210464.917.20<0.001BMI [kg/m2]11027.484.31711025.404.5740.0006Alat [U/l]a10937.028.0010823.513.0<0.001SBP [mmHg]110131.611.56110127.012.960.0063DBP [mmHg]11080.88.5211078.28.460.0223HbA1c [%]a355.901.00196.001.000.7603adue to lack of normality medians {Me} and interquartile ranges (IR) are presented (U Mann-Whitney test was used), in other cases means (x) and standard deviations (sd) (t Student test was used). Table 1Characteristic of studied variables in men and women.Table 1ParametersMenWomenpNx/Mesd/IRNx/Mesd/IRAge [yrs]11047.714.2311050.515.710.1729TC [mmol/l]1105.121.8791096.111.8420.0001HDL-C [mmol/l]1101.270.4111091.640.471<0.001LDL-C [mmol/l]1103.131.7311103.861.7000.0017TSH []a871.701.06991.511.070.2019TG [mmol/l]a1101.702.061101.190.870.0004Lp(a) [g/l]a1100.110.571100.200.500.0558Glucose [mmol/l]a835.390.86945.160.730.0003Creatinine [mg/l]a10580.617.210464.917.20<0.001BMI [kg/m2]11027.484.31711025.404.5740.0006Alat [U/l]a10937.028.0010823.513.0<0.001SBP [mmHg]110131.611.56110127.012.960.0063DBP [mmHg]11080.88.5211078.28.460.0223HbA1c [%]a355.901.00196.001.000.7603adue to lack of normality medians {Me} and interquartile ranges (IR) are presented (U Mann-Whitney test was used), in other cases means (x) and standard deviations (sd) (t Student test was used). Characteristic of studied variables in men and women. due to lack of normality medians {Me} and interquartile ranges (IR) are presented (U Mann-Whitney test was used), in other cases means (x) and standard deviations (sd) (t Student test was used). Table 2 shows clinical characteristics of patients. FH diagnosis was confirmed in 65 persons (56%) out of 116 patients in whom genetic analysis was performed. Increased Lp(a) serum concentrations above 0.3 g/L were found in 40% of men and 35.5% of women (p = ns). Coronary artery disease (CAD) was present in higher percentage of men than in women: 30 (27.8%) vs 17 (15.5%), p = 0.0325. Smoking habit was observed significantly more frequently in men: 46 (41,8%) than in women: 22 (20%), p = 0.0005. 88.2% of men and 80.9% of women were treated with statins, p = 0.1357. There were similar percentage of patients treated with statin among men and women with CAD (93.3 % and 94.1% respectively). Male and female patients with CAD were treated with statin more frequently than persons without CAD (93.3% vs 86,3% and 94.1% vs 78.5%, p < 0.05). Arterial hypertension and diabetes were found more frequently in men than in women (p ≤ 0.0158 and p = 0.0498 respectively).Table 2Clinical characteristics of patients.Table 2VariableMale N = 110Female N = 110pn%n%CAD3027.81715.50.0325Statin use9788.28980.90.1357Statin use among patients with CAD2893.31694.11.0000Statin use among patients without CAD6986.37378.50.2596Smoking4641.822200.0005Smoking among patients with CAD1963.3847.10.4370Smoking among patients without CAD2733.81415.10.0069Arterial hypertension9384.57770.00.0158Diabetes mellitus2522.71311.80.0498Lp(a) > 0.3 g/L44403935.50.713Obesity2220.02421.80.8683 Table 2Clinical characteristics of patients.Table 2VariableMale N = 110Female N = 110pn%n%CAD3027.81715.50.0325Statin use9788.28980.90.1357Statin use among patients with CAD2893.31694.11.0000Statin use among patients without CAD6986.37378.50.2596Smoking4641.822200.0005Smoking among patients with CAD1963.3847.10.4370Smoking among patients without CAD2733.81415.10.0069Arterial hypertension9384.57770.00.0158Diabetes mellitus2522.71311.80.0498Lp(a) > 0.3 g/L44403935.50.713Obesity2220.02421.80.8683 Clinical characteristics of patients. Men with CAD were significantly older (p < 0.001), had lower HDL-C concentrations (p < 0.0) and higher BMI (p < 0.01) than men without CAD. The median (IR) levels of Lp(a) were similar in men with and without CAD: 0.33 (0.67)g/l vs 0.09 (0.26) g/L, p = 0.0542 respectively. Table 3 present examined variables in men according to presence of CAD, after standardization by age. The mean values of Lp(a) (x, SE) standardized by age, also did not differ in men with and without CAD: 0.51 (0.089) vs 0.31 (0.053) g/L, p = 0.0684. The mean (SE) values of HDL- C were higher in men without CAD in comparison to men with CAD: 1.34 (0.046) vs 1.10 (0.076) mmol/L (p = 0.0098).Table 3Mean values of examined variables in men according to presence of CAD after adjustment for age.Table 3ParameterMen (N = 110)pCAD - absent (N = 80)CAD - present (N = 30)nxStd errnxStd errTC [mmol/l]805.240.209304.810.3500.3023HDL-C [mmol/l]801.340.046301.100.0760.0098LDL-C [mmol/l]803.180.192302.980.3210.6040TSH []621.890.112251.750.1810.5343TG [mmol/l]802.370.278302.580.4650.7058Lp(a) [g/l]800.310.053300.510.0890.0684Glucose [mmol/l]595.730.167245.930.2670.5497Creatinine [mg/l]7587.062.2843078.893.6940.0682BMI [kg/m2]8027.030.4673028.680.7820.0803Alat [U/l]8041.742.4972943.124.2560.7855SBP [mmHg]80131.21.30930132.62.1920.5924DBP [mmHg]8080.30.9643082.21.6150.3329HbA1c [%]205.900.175156.610.2040.0151 Table 3Mean values of examined variables in men according to presence of CAD after adjustment for age.Table 3ParameterMen (N = 110)pCAD - absent (N = 80)CAD - present (N = 30)nxStd errnxStd errTC [mmol/l]805.240.209304.810.3500.3023HDL-C [mmol/l]801.340.046301.100.0760.0098LDL-C [mmol/l]803.180.192302.980.3210.6040TSH []621.890.112251.750.1810.5343TG [mmol/l]802.370.278302.580.4650.7058Lp(a) [g/l]800.310.053300.510.0890.0684Glucose [mmol/l]595.730.167245.930.2670.5497Creatinine [mg/l]7587.062.2843078.893.6940.0682BMI [kg/m2]8027.030.4673028.680.7820.0803Alat [U/l]8041.742.4972943.124.2560.7855SBP [mmHg]80131.21.30930132.62.1920.5924DBP [mmHg]8080.30.9643082.21.6150.3329HbA1c [%]205.900.175156.610.2040.0151 Mean values of examined variables in men according to presence of CAD after adjustment for age. Women with CAD were significantly older (p < 0.001) and had lower total and LDL-C (p < 0.01) than women without CAD. Median (IR) values of Lp(a) were significantly higher in women with than without CAD: 0.69 (0.88) vs 0.16 (0.35) g/L, p = 0.0275. Systolic blood pressure values were higher and diastolic lower in women with CAD (p < 0.05). Table 4 present examined variables in women according to presence of CAD, after standardization by age. Women with CAD had lower total and LDL-C (p < 0.01) than women without CAD. However, the mean (SE) values of Lp(a), after standardization for age, were similar in women with and without CAD: 0.68 (0.156) vs 0.42 (0.064) g/L respectively. Standardized by age total and LDL-C were higher in women without CAD in comparison to women with CAD (x (SE) = 6.33 (0.188) mmol/l vs 4,91 (0.567) mmol/l, p = 0.0055 and 4.07 (0.171) mmol/l vs 2.68 (0.417), p = 0.0029). Also diastolic blood pressure standardized by age was higher in women without CAD (p < 0.05).Table 4Mean values of examined variables in women according to presence of CAD after adjustment for age.Table 4ParameterWomen (N = 110)pCAD - absent (N = 93)CAD - present (N = 17)nxStd errnxStd errTC [mmol/l]926.330.188174.910.4560.0055HDL-C [mmol/l]921.630.050171.710.1210.5338LDL-C [mmol/l]934.070.171172.680.4170.0029TSH []841.850.126151.340.3100.1367TG [mmol/l]931.500.128171.450.3110.8893Lp(a) [g/l]930.420.064170.680.1560.1263Glucose [mmol/l]815.180.122135.630.3160.1947Creatinine [mg/l]8870.462.5151658.696.1600.0847BMI [kg/m2]9325.740.4421723.571.0750.0689Alat [U/l]9229.181.9831623.984.9510.3391SBP [mmHg]93126.31.25017130.83.0430.1820HbA1c [%]166.140.25137.960.5990.0137 Table 4Mean values of examined variables in women according to presence of CAD after adjustment for age.Table 4ParameterWomen (N = 110)pCAD - absent (N = 93)CAD - present (N = 17)nxStd errnxStd errTC [mmol/l]926.330.188174.910.4560.0055HDL-C [mmol/l]921.630.050171.710.1210.5338LDL-C [mmol/l]934.070.171172.680.4170.0029TSH []841.850.126151.340.3100.1367TG [mmol/l]931.500.128171.450.3110.8893Lp(a) [g/l]930.420.064170.680.1560.1263Glucose [mmol/l]815.180.122135.630.3160.1947Creatinine [mg/l]8870.462.5151658.696.1600.0847BMI [kg/m2]9325.740.4421723.571.0750.0689Alat [U/l]9229.181.9831623.984.9510.3391SBP [mmHg]93126.31.25017130.83.0430.1820HbA1c [%]166.140.25137.960.5990.0137 Mean values of examined variables in women according to presence of CAD after adjustment for age. A multiple stepwise logistic regression analysis, including Lp(a), BMI, LDL-C, smoking status, diabetes and arterial hypertension adjusted for age was performed to examine associations between these variables and presence of CAD in men and women separately. Multiple stepwise logistic regression analysis showed that in the group of men only smoking and arterial hypertension were related to occurrence of CAD (Table 5). The analysis did not show significant association between Lp(a) concentration and CAD in examined group of men. Smokers have a nearly 3.5 times greater chance of developing CAD than non-smokers (OR = 3.49; p = 0.017). Arterial hypertension also increases the chance of developing CAD in men, although the result for hypertension should be treated with caution as the confidence interval for the odds ratio is wide. Table 6 presents the results of multiple stepwise logistic regression analysis exploring the association between CAD and examined variables in women and revealed that in women concentration of Lp (a), LDL-C and smoking habit were associated with CAD. The results showed that an increase in Lp(a) concentration by 1 g/L increases the chance of developing CAD more than twice (OR = 2.65; p = 0.036). Smokers have a nearly 8 times greater chance of developing CAD than non-smokers (OR = 8.03; p = 0.005, although it should be mentioned that the confidence interval for the odds ratio is wide.Table 5Association between examined variables and presence of CAD after adjustment for age in men.Table 5ParametersOR95% confidence intervalpLower limitUpper limitSmoking3.491.259.790.017HT16.364.9654.00<0.001Table 6Association between examined variables and presence of CAD after adjustment. for age in women.Table 6ParametersOR95% confidence intervalpLower limitUpper limitLp(a) [g/l]2.651.066.580.036LDL-C [mmol/l]0.430.240.750.003Smoking8.031.9034.030.005 Table 5Association between examined variables and presence of CAD after adjustment for age in men.Table 5ParametersOR95% confidence intervalpLower limitUpper limitSmoking3.491.259.790.017HT16.364.9654.00<0.001 Association between examined variables and presence of CAD after adjustment for age in men. Table 6Association between examined variables and presence of CAD after adjustment. for age in women.Table 6ParametersOR95% confidence intervalpLower limitUpper limitLp(a) [g/l]2.651.066.580.036LDL-C [mmol/l]0.430.240.750.003Smoking8.031.9034.030.005 Association between examined variables and presence of CAD after adjustment. for age in women. The results indicate sex-specific interactions between Lp(a) and CAD, supporting a role for Lp(a) in CAD development, particularly among hypercholesterolemic women. Discussion In this study we found in multiple regression model a significant relationship between Lp(a) concentration and prevalence of CAD in a group of women with primary hypercholesterolemia, intensively treated with statins. The association between cad and Lp (a) concentration in a group of men with primary hypercholesterolemia was not significant in our cohort. Our results are in agreement with data of Frohlich et al. who found association between Lp(a) and angiographically defined CAD in a group of women, but not in men [6]. Also Dal Pino B et al., in line with our data, showed that increased Lp (a) serum concentration was a strong independent predictor of mortality and non-fatal myocardial infarction in type 2 diabetes women, but not in type 2 diabetes men, or in patients without diabetes, however, their cohort did not include patients with FH [17]. On the other hand, in the Copenhagen General Population Study high lipoprotein(a) levels were associated equally with increased risk of morbidity and mortality in a large cohort of both women and men above 50 years of age [18]. Also, in a large U.S. pooled cohort, elevated Lp(a) levels predicted incident atherosclerotic vascular events similarly in both sex groups, in opposite to our findings [19]. Their data were confirmed by the results of the retrospective Mass General Brigham Lp(a) Registry, which showed that among individuals without prior atherosclerotic cardiovascular disease, elevated lipoprotein(a) was associated with higher rates of cardiovascular outcomes, particularly myocardial infarction, in both women and men [5]. In the JUPITER trial, in contrast to our results, there was no relationship of Lp(a) with CVD for women, and a strong association in men [20]. Also, Wang J. et al. in the subgroup analysis of a large cohort of persons with (8070) and without CVD (400) found that elevated Lp(a) levels accelerated the process of atherosclerotic vascular disease especially in males, as well as hypertensive, diabetic patients, and non-smokers [21]. Interestingly Cook et al. found that Lp(a) was associated with cardiovascular disease in WHS and WHI cohorts of women from primary prevention, only among those with high levels of total cholesterol, above 220 mg/dl [22]. Moreover, in the study by Ao L. et al. including 127,958 unrelated European-ancestry participants from UK Biobank (54.7 % women) without a baseline history of CAD, Lp(a)-associated CAD risk seemed to particularly affect those having levels of total-C, LDL-C and triglycerides above the thresholds from clinical guidelines [23]. These data, showing that in women with high cholesterol, Lp(a) concentration is associated with CAD support our observation, as FH patients are characterized by elevated total and LDL-C levels. Associations of Lp(a) and CAD in our group of women with primary hypercholesterolemia were present despite treatment with statin, what is in agreement with observation that Lp(a) predicts risk also among those with low values of LDL-C levels secondary to statin treatment [4,20]. Moreover, the Multi-Ethnic Study of Atherosclerosis (MESA) showed that elevated plasma Lp(a) concentration was associated with increased CVD risk also when LDL-C was low in individuals not on statin therapy. These results indicate that when Lp(a) was elevated, risk of CHD events increased, regardless of baseline LDL-C, in line with our observations in FH women [24]. The mechanism of sex difference of Lp (a) and CAD association is difficult to explain. Elevated Lp(a) levels are associated with increased atherogenicity and also with increased prothrombotic/antifibrinolytic and pro-inflammatory state [8,25]. Lp(a) levels are modulated by hormonal factors, including testosterone levels, menopause, and hormone replacement therapy [[26], [27], [28], [29], [30]]. In women in the Copenhagen General Population Study Lp(a) levels were higher after menopause, and slightly lower during hormone replacement therapy [18]. Moreover, the relationship between high Lp(a) levels and increased CVD risk is modified by hormone therapy [28]. Concentrations of Lp(a) are reported to be 17% higher in post-menopausal women than in men [30]. The mean age of women in our cohort was 50 years, which corresponds to the average age of menopause, however, individual menopausal status was not available in our study. There is a growing body of evidence that elevated lipoprotein(a) levels above the age of 50 may represent a relatively more important risk factor in women than in men [18,30]. Costello BT et al. reported a high prevalence of elevated Lp(a) among women presenting to Heart Centers for Women and concluded that elevated Lp(a) may help identify women who could benefit from aggressive risk-factor modification and pharmacologic therapy, even in the absence of traditional risk markers such as elevated LDL-C or high ASCVD risk [31]. Our results, in line with previous studies, suggest potential implications for cardiovascular risk stratification in women with primary hypercholesterolemia, particularly in the context of emerging Lp(a)-lowering therapies. Novel therapeutic approaches have demonstrated the ability to reduce Lp(a) concentrations by up to 80% [30,32]. The inverse association between LDL-C and CAD observed in a group of women in our study is explained by treatment effect. Patients with established coronary artery disease were more frequently treated with statins, which resulted in lower LDL-C levels at the time of measurement. Limitations of this study are related to its retrospective design, the single-center experience, as well as the lack of availability of information on menopausal status in female patients, the relatively small number of patients with coronary artery disease, and the fact that genetic confirmation of familial hypercholesterolemia was available only in a subset of patients. Lp(a) was measured using latex-enhanced immunonephelometry and reported in mass concentration (g/L). This method is subject to isoform size variability, which may affect comparability with molar-based assays and should be considered when interpreting the results. In summary, our data suggest that Lp(a) is more strongly associated with CAD in women with primary hypercholesterolemia than in men, and that measurement and treatment of elevated Lp(a) in this group of women may contribute to CAD prevention. Sustained optimal LDL-C lowering, together with the introduction of emerging Lp(a)-lowering therapies and management of other interrelated risk factors, such as remnant cholesterol and inflammation, may be effective in maximally reducing cardiovascular risk [33]. Atherosclerotic vascular mortality is now increasing, especially in middle-aged women, so there is a need to treat all cardiovascular risk factors, particularly in FH women, to reduce the unacceptably high atherosclerosis burden in women [34]. MWM was supported by a grant from Jagiellonian University Medical College (N41/DBS/001328). Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.